Illumina agrees to buy cancer-detection start-up Grail for $8bn
Grail, whose list of high-profile investors includes Bill Gates and Jeff Bezos, is developing a blood test that aims to detect multiple cancers
21 September 2020 - 17:37
Genetic sequencing giant Illumina has agreed to acquire Grail in a deal valuing the cancer-detection start-up at $8bn.
Grail shareholders will receive $3.5bn in cash and $4.5bn in Illumina common stock, the companies said in a statement on Monday. Both companies’ boards of directors have approved the transaction...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.